

**ASX Announcement****Summary of Key Terms of CEO Employment Agreement****SYDNEY Australia 19 February 2010:**

We refer to the announcement made by the Company in relation to the appointment of Jeffrey Goodman as CEO and Managing Director. The Company provides the following information in relation to Mr Goodman's employment agreement with CathRx.

<b>Term</b>	There is no fixed term of employment. The agreement is able to be terminated as set out below.
<b>Remuneration</b>	<p><i>Fixed Remuneration</i> - Mr Goodman's fixed remuneration is \$250,000 per annum inclusive of compulsory superannuation contributions.</p> <p><i>Long Term Incentives - Employee Options</i> - Mr Goodman will be granted 1,000,000 options under the Company's employee option plan subject to receipt of shareholder approval which will be sought at the next general meeting of the Company. The options will vest over three years.</p>
<b>Termination of Employment</b>	Mr Goodman's employment may be terminated by either Mr Goodman or the Company with one month's written notice. CathRx may terminate Mr Goodman's employment immediately in certain events including serious misconduct and material breach of contract.
<b>Other terms</b>	The employment agreement contains usual confidentiality, intellectual property and non compete provisions.

Further details will be provided in the Company's Remuneration Report as required by the *Corporations Act (Cth) 2001*.

**End**

**About CathRx**

CathRx is a medical device company which manufactures and markets advanced cardiac catheter solutions for the treatment of people suffering from electrical problems of the heart known as cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx's diagnostic products are now being sold in Europe.

**About cardiac arrhythmias**



CathRx Ltd  
ABN 23 089 310 421

5 Parkview Drive  
Homebush Bay NSW 2127  
Australia  
Telephone +61 (0)2 9397 5700  
Facsimile +61 (0)2 9397 5701  
[www.cathrx.com](http://www.cathrx.com)

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

***For further information:***

Jeffrey Goodman  
CathRx Chief Executive Officer  
Telephone: +61 2 9397 5700

Amanda Wong  
CathRx Chief Financial Officer  
Telephone: +61 2 9397 5700

